NASDAQ:OASM Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free OASM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$1.30▼$1.6252-Week Range$0.94▼$5.70VolumeN/AAverage Volume98,414 shsMarket Capitalization$1.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Oasmia Pharmaceutical AB (publ) alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Oasmia Pharmaceutical AB (publ)Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Read More Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. OASM Stock News HeadlinesApril 30, 2024 | seekingalpha.comBOEUF Bonesupport Holding AB (publ)March 23, 2024 | morningstar.comLipigon Pharmaceuticals AB LPGOMay 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 6, 2024 | gurufocus.comLSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comOasmia Pharmaceutical AB (publ) - Special Call TranscriptFebruary 8, 2024 | finance.yahoo.comResurs Holding AB (publ) (RESURS.ST)January 6, 2024 | morningstar.comQuiaPEG Pharmaceuticals Holding AB QUIANovember 29, 2023 | investing.comNewbury Pharmaceuticals AB (NEWBRY)May 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.September 14, 2023 | investing.comLipigon Pharmaceuticals AB (LPGO)August 25, 2023 | investing.comSpeqta publ AB (SPEQT)August 25, 2023 | seekingalpha.comPRXXF Paradox Interactive AB (publ)February 26, 2023 | seekingalpha.comOXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2MMarch 11, 2022 | stockhouse.comOrexo appoints Fredrik Järrsten as new CFONovember 29, 2021 | finanznachrichten.deNotice of extra general meeting in Terranet ABJuly 22, 2021 | investing.comFancy Wood Industries PCL (FANCY)See More Headlines Receive OASM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oasmia Pharmaceutical AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OASM CUSIPN/A CIK1607245 Webwww.oasmia.com Phone(461) 850-5440FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,950,000.00 Net Margins-8,633.64% Pretax MarginN/A Return on Equity-43.94% Return on Assets-28.92% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.73 Sales & Book Value Annual Sales$220,000.00 Price / Sales6.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.03Miscellaneous Outstanding Shares74,967,000Free FloatN/AMarket Cap$1.50 million OptionableNot Optionable Beta0.96 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesFrançois R. MarteletChief Executive OfficerFredrik JärrstenChief Financial OfficerMikael AspChief Technology OfficerNigel GoodmanDirector-Clinical OperationsCarina EklöwDirector-Global Medical AffairsKey CompetitorsHistogenNASDAQ:HSTOPanbela TherapeuticsNASDAQ:PBLALucy Scientific DiscoveryNASDAQ:LSDINeuBase TherapeuticsNASDAQ:NBSEGRI BioNASDAQ:GRIView All Competitors OASM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oasmia Pharmaceutical AB (publ) investors own include G1 Therapeutics (GTHX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), Verastem (VSTM), Akari Therapeutics (AKTX), Nightstar Therapeutics (NITE), Novavax (NVAX) and OpGen (OPGN). This page (NASDAQ:OASM) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldCharles Payne Demystifies OptionsUnstoppable ProsperityThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.